Did You Know...
...that the x-ray was discovered purely by accident? When German physicist Wilhelm Konrad von Roentgen was experimenting with cathode rays in 1895, he put an activated Crookes tube in a book and went out to lunch. When he returned, he discovered that a key that had also been placed in the book showed up as an image on the developed film!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7592465 | Fertilizer/plant vitalizer Contamination by microorganism of an aqueous proline solution is prevented by adjusting a proline concentration of the solution to 20% (W/W/) or more. Such solutions are useful as fertilizers and/or plan vitalizers. Preservation of the novel solutions are possible o... | 09/22/2009 |
| 7371871 | Inhibitors of glutaminyl cyclase The present invention relates to compounds that act as inhibitors of QC including those represented by the general formulae 1 to 9: and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's di... | 05/13/2008 |
| 7368421 | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis The present invention provides a new use of DP IV-inhibitors. The compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, are useful in treating conditions mediated by DP IV or DP IV-like enzymes, such as imm... | 05/06/2008 |
| 7368576 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for treating conditions mediated by DPIV or DPIV-like enzymes, such as cancer and tumors. In a more pre... | 05/06/2008 |
| 7335645 | Effectors of dipeptidyl peptidase IV for topical use The invention relates to compounds for topically influencing the activity of dipeptidyl peptidase of the general formula wherein A is an amino acid having at least one f... | 02/26/2008 |
| 7230119 | Process for the preparation of substituted pyrrolidine derivatives and intermediates Two syntheses are provided; one for the preparation of (3R,4R)-4-(hydroxymethyl)pyrrolidin-3-ol, and other for the preparation of (3S,4R)-4-(hydroxymethyl)pyrrolidin-3-ol. (3R,4R)-4-(hydroxymethyl)pyrrolidin-3-ol is prepared using the achiral ylide prepared from ben... | 06/12/2007 |
| 7230074 | Inhibitors of dipeptidyl-aminopeptidase type IV Peptide inhibitors of dipeptidyl-aminopeptidase type IV (DP-IV) are provided. The peptide inhibitors have an isomeric purity of about 96–99 percent. The peptide inhibitors include one or more amino acids covalently coupled to boroproline moiety. The compounds are ... | 06/12/2007 |
| 7196201 | Pyrrolidines as dipeptidyl peptidase inhibitors The present invention relates to novel compounds, their use for inhibiting serine proteases, such as dipeptidyl peptidases, such as dipeptidyl peptidase IV (DPP-IV) and to methods for their production and their therapeutic utility | 03/27/2007 |
| 7166579 | Prodrugs of DP IV-inhibitors Prodrug compounds of unstable inhibitors of the serine peptidase dipeptidyl peptidase IV, are used in the treatment of various disorders, especially of metabolic disorders. The Prodrug compounds can be used in the treatment of impaired glucose tolerance, glucosuria,... | 01/23/2007 |
| 7166580 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, su... | 01/23/2007 |
| 7144856 | Inhibitors of dipeptidyl peptidase I The present invention relates to specific inhibitors of the cysteine protease dipeptidyl peptidase I (DP I)which can be used in the treatment of malignant cell degeneration, immune diseases impaired wound healing and metabolic diseases of humans and are represented ... | 12/05/2006 |
| 7132104 | Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders The present invention discloses a method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of... | 11/07/2006 |
| 7109347 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for treating conditions mediated by DPIV or DPIV-like enzymes, such as cancer and tumors. In a more pre... | 09/19/2006 |
| 7070941 | Methods and compositions for tagging via azido substrates The invention provides methods and compositions for azide tagging of biomolecules. In one embodiment of the invention, proteins are tagged by metabolic incorporation of prenylated azido-analog substrates. Examples of such analogs are azido farnesyl diphosphate and a... | 07/04/2006 |
| 7053055 | Compounds of unstable DP IV-inhibitors Novel compounds of unstable inhibitors of the serine peptidase dipeptidyl peptidase IV, are used in the treatment of various disorders, especially of metabolic disorders. The compounds can be used in the treatment of impaired glucose tolerance, glucosuria, hyperlipi... | 05/30/2006 |
| 6992067 | Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.... | 01/31/2006 |
| 6949658 | Process for producing optically active α-amino acid and optically active α-amino acid amide The present invention provides a process for efficiently producing an optically active α-amino acid and an optically active α-amino acid amide. After contacting with cells or processed cells thereof having an ability to asymmetrically hydrolyse, a water solvent is... | 09/27/2005 |
| 6949515 | Effectors of dipeptidyl peptidase IV for topical use The invention relates to compounds for topically influencing the activity of dipeptidyl peptidase of the general formula wherein A is an amino acid having at least ... | 09/27/2005 |
| 6946480 | Glutaminyl based DPIV inhibitors The present invention provides compounds of the formula: wherein X═CH2 or S or pharmaceutical acceptable salts thereof useful for treating conditions mediated by DPIV or DPIV-like enzymes, such as arthriti... | 09/20/2005 |
| 6939855 | Anti-inflammatory compositions and method The disclosed invention includes pharmaceutical compositions and methods for treating inflammatory conditions, particularly those that are characterized by increased binding of alpha-9 integrin to one or more of its ligands. Also disclosed are methods for selecting ... | 09/06/2005 |
| 6911467 | Antidiabetic agents Compounds which are 1-(2′-aminoacyl)-2-cyanopyrrolidine derivatives according to general formula (1) are DP-IV inhibitors for treatment of impaired glucose tolerance or type 2 diabetes; wherein A is selected from groups (2, 3 and 4); X is selected from aminoacyl g... | 06/28/2005 |
| 6903075 | Heterocyclic amide compounds as cell adhesion inhibitors Compounds of Formula I are antagonists of VLA-4 and/or α4β7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions an... | 06/07/2005 |
| 6884782 | STAT modulators The present invention provides compounds, compositions and methods for the inhibition or treatment of conditions or disorders modulated by the STAT transcription factors, particularly STAT4 and STAT6. Additionally, the compounds are useful for the diagnosis of condi... | 04/26/2005 |
| 6875737 | Multivalent compounds for crosslinking receptors and uses thereof Synthetic crosslinking homobivalent and heterobivalent compounds have been designed and developed. These compounds are low in molecular weight, have antagonistic or agonistic activity, and induce the association between two identical or similar natural receptors (ho... | 04/05/2005 |
| 6872805 | Hepatitis C virus inhibitors The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and me... | 03/29/2005 |
| 6673772 | Dipeptide compounds and their use as antiviral agents A novel dipeptide compound inhibiting the enzymatic activity of HIV protease and an anti-AIDS medicine comprising this dipeptide compound as an effective component represented by formula (I) ##STR1## wherein R1, R2, and R3... | 01/06/2004 |
| 6645939 | Substituted ଲ-alanine derivatives as cell adhesion inhibitors ଲ-Alanine derivatives of Formula I are antagonists of VLA-4 and/or 댔ଲ.sub.7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated in... | 11/11/2003 |
| 6632950 | Process for the preparation of derivatives of 4-amino-3-hydroxypyrrole-2-carboxylic acid Novel processes and intermediates are provided for the synthesis of derivatives of 4-amino-3-hydroxypyrrole-2-carboxylic acids that are useful as monomers for polyamides capable of binding dsDNA. According to one preferred reaction scheme, an alkyl alkoxy... | 10/14/2003 |
| 6632825 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis Compounds of the formula: ##STR1## where the formula variables are as defined in the disclosure, advantageously inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions containi... | 10/14/2003 |
| 6627760 | Amorphous compound The present invention relates to a novel form of (S)-1-[N2 -(1-carboxy-3-phenylpropyl]-L-lysyl]-L-proline known under the generic name lisinopril. Further, the present invention also relates to the use of the novel amorphous form of lisinopril ... | 09/30/2003 |
| 6613879 | FAP-activated anti-tumour compounds The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP), said prodrug having a cleavage site which is recognised by FAP, and said drug being cytot... | 09/02/2003 |
| 6559127 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g.... | 05/06/2003 |
| 6552038 | Anticoagulant agents This invention relates to a compound of the Formula I X--C(O)--Y--G--R I (wherein X, Y, G and R have the values defined in the description), or a pharmaceutically acceptable salt thereof, processes and intermediates for the preparation of such a compound or ... | 04/22/2003 |
| 6515179 | Process for the removal of nitrobenzenesulfonyl A 2- or 4-nitrobenzenesulfonamide is allowed to react with an alkali metal alkoxide to remove a nitrobenzenesulfonyl group to thereby obtain an amine corresponding to the amide. Furthermore, a method for producing an amine derivative by allowing the resul... | 02/04/2003 |
| 6509477 | Small molecule inhibitors of rotamase enzyme activity This invention relates to neurotrophic compounds having an affinity for FKBP-type immunophilins, their preparation and use as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase... | 01/21/2003 |
| 6489300 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g.... | 12/03/2002 |
| 6462173 | Inhibitors of phosphoserine and phosphothreonine-proline-specific isomerases Inhibitors of phosphoserine- or posphothreonine-specific peptidyl prolyl isomerases are described. Such inhibitors include molecules that mimic the structure and conformation of the pSer/pThr-Pro peptide moiety of the isomerase substrate when the substrat... | 10/08/2002 |
| 6458769 | Amorphous compound The present invention relates to a novel form of (S)-1-[N2 -(1-carboxy-3-phenylpropyl]-L-lysyl]-L-proline known under the generic name lisinopril. Further, the present invention also relates to the use of the novel amorphous form of lisinopril ... | 10/01/2002 |
| 6440937 | Dipeptide benzamidine as a kininogenase inhibitor Compounds of the formula I ##STR1## where R, R1, R2, R3, R4, R5 and R6, and l, m and n have the meanings stated in the description, and their preparation are described. The novel compounds ... | 08/27/2002 |
| 6432923 | VLA-4 antagonists Compounds of the formula I ##STR1## as defined, and their pharmaceutically acceptable salts are VLA-4 antagonists which are useful in inhibiting cell adhesion and in the therapeutic or prophylactic treatment of inflammatory and autoimmune diseases, p... | 08/13/2002 |
